Loading the section…

NEUP: financial statements from SEC — TradeAlmanac

NEUP

Neuphoria Therapeutics Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	31/12/2025	30/09/2025	31/03/2025	31/12/2024	30/09/2024
Revenue	—	—	—	15M	662,715	—
Research and development	—	697,723	4M	2M	2M	2M
Selling, general and administrative	2M	2M	2M	1M	3M	2M
Operating expenses	1M	4M	6M	3M	4M	4M
Operating income	−1M	−4M	−6M	12M	−4M	−4M
Pre-tax income	−539,856	2M	−10M	11M	−2M	−936,974
Income tax	−34,793	−34,794	−34,793	−81,186	11,609	−132,187
Net income	−505,063	2M	−10M	11M	−2M	−804,787
Earnings per share	−0.09	0.41	−4.41	6.55	−1.23	−0.62
Earnings per share, diluted	−0.09	−0.77	−4.41	6.55	−1.79	−0.62
Weighted average shares	5M	5M	2M	2M	2M	1M
Weighted average shares, diluted	5M	5M	2M	2M	2M	1M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/01/2025	31/12/2024	30/09/2024
Cash and equivalents	19M	22M	14M	14M	17M	—	4M	8M
Receivables	2M	1M	1,758

Cash flow

Metric	30/09/2025	30/09/2024
Operating cash flow	−4M	−4M
Depreciation and amortisation	165,792	165,713
Share-based compensation	111,277	26,736
Financing cash flow	3M	−227,338

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator